常宝股份(002478) - 2023 Q1 - 季度财报

Financial Performance - Revenue for Q1 2023 reached CNY 1.82 billion, a 68.15% increase compared to CNY 1.08 billion in the same period last year[5] - Net profit attributable to shareholders was CNY 198.58 million, up 410.18% from CNY 38.92 million year-on-year[5] - Basic and diluted earnings per share were both CNY 0.22, reflecting a 450.00% increase from CNY 0.04 in the same quarter last year[5] - The company reported a net profit margin improvement, with net profit figures to be detailed in subsequent reports[24] - The net profit for the first quarter of 2023 was CNY 201,360,635.44, compared to CNY 42,642,954.68 in the same period last year, representing a significant increase[25] - The operating profit for the first quarter was CNY 190,835,308.36, up from CNY 40,704,306.81 year-over-year[25] - The total profit for the first quarter was CNY 228,684,774.93, compared to CNY 41,333,272.70 in the same period last year, showing substantial growth[25] - The company’s total comprehensive income for the first quarter was CNY 200,801,409.86, compared to CNY 44,689,482.51 in the same quarter last year, highlighting overall financial improvement[25] Cash Flow and Assets - Net cash flow from operating activities increased to CNY 319.73 million, a significant rise of 1,307.85% compared to CNY 22.71 million in the previous year[5] - Cash flow from operating activities generated a net amount of CNY 319,726,749.55, compared to CNY 22,710,359.14 in the previous year, indicating strong operational cash generation[27] - Cash and cash equivalents at the end of the period were ¥1,985,836,534.74, an increase of 37.5% from ¥1,443,656,629.06 at the beginning of the year[21] - Cash and cash equivalents at the end of the period totaled CNY 1,403,919,381.57, up from CNY 609,706,471.71 at the end of the previous year[28] - Total assets at the end of Q1 2023 were CNY 7.78 billion, a 6.01% increase from CNY 7.34 billion at the end of the previous year[5] - The company's total assets as of March 31, 2023, amounted to ¥7,776,256,309.49, up from ¥7,335,394,006.38 at the beginning of the year, reflecting a growth of 6.0%[22] Liabilities and Shareholder Information - Short-term borrowings increased by 47.40% to CNY 643.17 million, reflecting a rise in short-term financing needs[9] - The total liabilities increased to ¥2,860,348,628.82, compared to ¥2,596,364,525.52 at the start of the year, marking an increase of 10.1%[22] - The equity attributable to shareholders of the parent company rose to ¥4,753,569,884.87, up from ¥4,579,471,301.21, indicating a growth of 3.8%[22] - The total number of common shareholders at the end of the reporting period is 23,913[14] - The largest shareholder, Mr. Cao Jian, holds 24.79% of the shares, totaling 165,537,960 shares[14] - The company’s major shareholders include Jiangsu Changbao Investment Development Co., Ltd., holding 5.60% of the shares[14] - The company has no preferred shareholders as of the reporting period[16] Research and Development - Research and development expenses increased by 50.13% to CNY 7.05 million, driven by enhanced efforts in new product development[12] - Research and development expenses increased to ¥70,477,239.55, representing a rise of 50.3% compared to ¥46,942,606.69 in the previous year[24] Other Financial Activities - The company has repurchased 6,032,000 shares at a total cost of approximately RMB 30,273,928.77 as of March 31, 2023[18] - The company plans to use its own funds to repurchase shares at a price not exceeding RMB 5.80 per share, with a total repurchase amount between RMB 30 million and RMB 60 million[18] - The company has received a total of RMB 300.7 million from the sale of medical assets, with RMB 50 million received by November 30, 2022, and the remaining RMB 420 million still pending[16] - The company has completed the performance compensation obligations related to Weifang Jiayuan Construction Materials Testing Co., Ltd., as mandated by the court[17] - The company incurred a credit impairment loss of CNY 23,916,219.34, compared to a gain of CNY 1,723,689.65 in the previous year, indicating increased credit risk[25] - The company experienced a 1,487.50% increase in credit impairment losses, primarily due to provisions for bad debts[13] - Operating profit from non-operating income surged by 1,832.11% to CNY 35.93 million, mainly from performance compensation income[13] - Total operating costs for Q1 2023 were ¥1,594,449,694.07, up 53.0% from ¥1,043,038,135.84 in Q1 2022[24] - Total revenue from sales of goods and services received cash of CNY 1,424,065,503.38, an increase from CNY 950,164,971.04 in the prior year[27] Future Outlook - The company’s future outlook includes continued focus on share repurchase and potential market expansion strategies[18] - The company’s stock is subject to various pledges and restrictions, with specific shares pledged by certain shareholders[14]